Company Description

Lysoway Therapeutics is developing highly brain-penetrant lysosomal ion channel modulators, including TRPML1 and TMEM175 agonists, to restore autophagy-lysosomal function in age-related neurodegenerative diseases such as Alzheimer’s and Parkinson’s, as well
as rare lysosomal disorders.